FluoroPharma Medical, Inc. (FPMI) Takes On the CAD Stress Test
FluoroPharma, a developer of imaging agents used in association with positron emission tomography (PET) scanning, was founded in 2003 by Dr. David Elmaleh, currently the company’s Chief Scientific Officer, who has gathered around him some of the most knowledgeable people in the radiopharmaceutical and medical technology industries. Together they are developing a protected portfolio of PET tracer agents, including their lead products, CardioPET, BFPET, and VasoPET, designed for use in evaluating different processes associated with coronary artery disease (CAD), the country’s #1 killer. Nearly one-third of all Americans are believed to have some form of cardiovascular disease. People with CAD…